SOFTMEDX-NEW0648.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, SOFTMEDX-NEW (0648.HK) trades at a P/E of 5.06x, P/B of 1.30x, P/S of 0.63x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 36th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/B sits at the 34th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 42nd percentile within its industry and the 18th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Cross-checking P/E against P/B, the two percentiles sit within 2.5 points of each other — a consistent signal from both angles. The P/E percentile sits lower across the market than within its own industry — relatively cheaper next to the market as a whole. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. SOFTMEDX-NEW operates in the Comprehensive II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 0648 · SEHK: 0648 · 0648
Want the full picture on whether SOFTMEDX-NEW (0648.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 5.06 | ||||||
| P/B (MRQ) | 1.30 | ||||||
| P/S (TTM) | 0.63 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |